Internal Medicine, Nephrology · Oklahoma City, OK
NPI
1003956285
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
4221 S Western Ave, Suite 5020
Oklahoma City, OK, 73109
Phone (405) 644-5428
Groups this clinician bills Medicare through
Medicare paid, 2024
$347K
4,293 services
Medicare patients, 2024
744
Average age 74
Drug cost, 2024
$2.0M
7,817 prescriptions
Company payments, 2025
$654
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fazal A Ali was code 99232 (hospital e&m - subsequent), 1,156 times for 223 patients. In total Fazal A Ali billed 4,293 services in 21 codes, and Medicare paid $347K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,156 | 223 | $58.21 | $67K |
| 99214 Office E&M - Established | Office | 910 | 419 | $85.52 | $78K |
| 99457 E&M - Miscellaneous | Office | 588 | 98 | $35.37 | $21K |
| 99454 E&M - Miscellaneous | Office | 301 | 73 | $32.25 | $9,706 |
| 99223 Hospital E&M - Initial | Facility | 285 | 216 | $124.02 | $35K |
| 99233 Hospital E&M - Subsequent | Facility | 246 | 113 | $86.74 | $21K |
| 90960 ESRD Related Services (not dialysis) | Office | 223 | 52 | $257.22 | $57K |
| 99213 Office E&M - Established | Office | 104 | 96 | $59.20 | $6,156 |
| 99458 E&M - Miscellaneous | Office | 84 | 46 | $28.72 | $2,413 |
| 99453 E&M - Miscellaneous | Office | 83 | 83 | $13.72 | $1,139 |
| 90961 ESRD Related Services (not dialysis) | Office | 74 | 48 | $214.45 | $16K |
| 99204 Office E&M - New | Office | 65 | 65 | $108.74 | $7,068 |
| 99291 Critical Care E&M | Facility | 56 | 18 | $158.30 | $8,865 |
| 99222 Hospital E&M - Initial | Facility | 36 | 35 | $97.11 | $3,496 |
By year: 2022 $339K for 3,755 services; 2023 $321K for 3,409 services; 2024 $347K for 4,293 services.
Medicare prescription drug claims, 2024
In 2024, the drug Fazal A Ali prescribed most often to Medicare patients was Amlodipine Besylate, with 1,004 prescriptions and refills. In total Fazal A Ali wrote 7,817 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 1,004 | 2,326 | 328 | $7,399 |
| Hydralazine Hcl Generic | 675 | 1,694 | 230 | $8,377 |
| Farxiga Dapagliflozin Propanediol | 491 | 1,035 | 152 | $561K |
| Furosemide Generic | 473 | 1,122 | 179 | $1,805 |
| Lisinopril Generic | 313 | 795 | 107 | $1,776 |
| Torsemide Generic | 279 | 581 | 104 | $4,843 |
| Metolazone Generic | 208 | 393 | 66 | $4,955 |
| Potassium Chloride Generic | 200 | 374 | 65 | $1,708 |
| Famotidine Generic | 194 | 439 | 56 | $3,479 |
| Jardiance Empagliflozin | 167 | 378 | 55 | $219K |
| Doxazosin Mesylate Generic | 164 | 383 | 55 | $2,838 |
| Tamsulosin Hcl Generic | 158 | 396 | 51 | $2,467 |
| Finasteride Generic | 151 | 356 | 40 | $1,727 |
| Losartan Potassium Generic | 149 | 417 | 59 | $1,378 |
| Atorvastatin Calcium Generic | 146 | 360 | 60 | $1,320 |
Brand drugs: - claims; generic drugs: 6,381 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fazal A Ali $654 ($654 in general payments such as food, travel and fees) from 15 companies. The largest payer was Amgen Inc. with $92.26.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 4 | $92.26 |
| Travere Therapeutics, Inc. TVTX | 12 | $84.58 |
| Novo Nordisk Inc NVO | 3 | $66.09 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $62.68 |
| GlaxoSmithKline, LLC. GSK | 3 | $61.7 |
| Fresenius USA Marketing, Inc. | 3 | $59.65 |
| Akebia Therapeutics Inc AKBA | 2 | $36.23 |
| Janssen Biotech, Inc. JNJ | 1 | $35 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $31.44 |
| Pharmacosmos Therapeutics Inc. | 1 | $25.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.